A phase 3, open-label, parallel-group study to evaluate the dosing regimens of human lymphoblastoid interferon (HLBI) in hepatitis C patients with compensated cirrhosis.
Latest Information Update: 17 Jun 2016
At a glance
- Drugs Interferon alpha-n1 (Primary)
- Indications Liver cirrhosis
- Focus Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 17 Jun 2016 New trial record